Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Patients With CKD: A Subgroup Analysis of the Randomized Controlled RxEACH Trial

Slides:

Advertisements

Similar presentations

Ross T. Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC Yazid NJ Al Hamarneh, BPharm, PhD Charlotte Jones, MD, PhD, FRCP(C) Brenda Hemmelgarn, MD, PhD, FRCP(C)

Advertisements

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on.

American Journal of Kidney Diseases

Implementing KDOQI CKD Definition and Staging Guidelines in Southern California Kaiser Permanente Mark Rutkowski, MD, Wendy Mann, PharmD, Stephen Derose,

Renal Function Testing

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

Phosphate Kinetic Models in Hemodialysis: A Systematic Review

Metabolic Complications in Elderly Adults With CKD

Care of the Undocumented Immigrant in the United States With ESRD

Quiz Page March 2008 American Journal of Kidney Diseases

Empirically Derived Search Filters for the Development of Kidney Disease Clinical Practice Guidelines Pavel S. Roshanov, MD, MSc, Arthur V. Iansavichus,

A Decade After the KDOQI CKD Guidelines

World Kidney Day 2014: CKD and the Aging Population

Sustainable Community-Based CKD Screening Methods Employed by the National Kidney Foundation's Kidney Early Evaluation Program (KEEP) Peter A. McCullough,

NSAID Use and Progression of Chronic Kidney Disease

Erratum Regarding “Preemptive Correction of Arteriovenous Access Stenosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials” (Am.

Joseph A. Vassalotti, MD, Beth Piraino, MD, Lynda A. Szczech, MD

Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-

Meaghan Lunney, Raymond Lee, Karen Tang, Natasha Wiebe, Aminu K

I. Introduction American Journal of Kidney Diseases

Evaluation of the Potential Living Kidney Donor

Differences in Use of Peritoneal Dialysis and Survival Among East Asian, Indo Asian, and White ESRD Patients in Canada Brenda R. Hemmelgarn, PhD, MD,

Focusing on Health Literacy Might Help Us Cross the Quality Chasm

Daniel E. Weiner, MD, MS American Journal of Kidney Diseases

Salt and Hypertension American Journal of Kidney Diseases

Guidelines for the Older Adult With CKD

Augmented Nurse Care Management in CKD Stages 4 to 5: A Randomized Trial Steven Fishbane, MD, Sofia Agoritsas, MPA, Alessandro Bellucci, MD, Candice Halinski,

Erratum Regarding “Ultrasound Monitoring to Detect Access Stenosis in Hemodialysis Patients: A Systematic Review” (Am J Kidney Dis. 2008;51(4): )

Prehypertension and Incidence of ESRD: A Systematic Review and Meta-analysis Yuli Huang, MD, Xiaoyan Cai, MD, Jianyu Zhang, MD, Weiyi Mai, MD, PhD, Sheng.

Joseph A. Vassalotti, MD, Lesley A. Stevens, MD, MS, Andrew S

Yousef Rezaei, MD American Journal of Kidney Diseases

Hypomagnesemia in a Patient With an Eating Disorder

Warfarin Initiation, Atrial Fibrillation, and Kidney Function: Comparative Effectiveness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation

Hemoglobin Level and Transfusions in Patients on Maintenance Dialysis: Where the Rubber Meets the Road Eduardo Lacson, MD, MPH, Franklin Maddux, MD

Navdeep Tangri, MD, FRCPC, Daniel E. Weiner, MD, MS

A Decade After the KDOQI CKD Guidelines: A Historical Perspective

Effect of Intensive Insulin Therapy and Pentastarch Resuscitation on Acute Kidney Injury in Severe Sepsis George Thomas, MD, MPH, Ethan M. Balk, MD,

David C. Mendelssohn, MD, FRCPC, Jay B. Wish, MD

Sankar D. Navaneethan, MD, MPH, Suetonia C. Palmer, MBChB, Jonathan C

Use of Diuretics in Heart Failure: A Precarious Balance

A Decade After the KDOQI CKD Guidelines: A Perspective From Mexico

Kidney Disease Among African Americans: A Population Perspective

CPR 1.2.: Evaluation of Anemia in CKD

Impact of a Primary Care CKD Registry in a US Public Safety-Net Health Care Delivery System: A Pragmatic Randomized Trial Delphine S. Tuot, Charles E.

Performance of GFR Estimating Equations Stratified by Measured or Estimated GFR: Implications for Interpretation Jonas Björk, PhD, Anders Grubb, MD,

Beef Tea, Vitality, Creatinine, and the Estimated GFR

Christina L. Klein, MD, Daniel C. Brennan, MD, FACP

Quiz Page April 2008 American Journal of Kidney Diseases

Study Designs in Patient-Oriented Research

Evidence and Outcomes in CKD

Dennis G. Moledina, MD, Mark A. Perazella, MD

Daniel E. Weiner, MD, MS, Mark J. Sarnak, MD, MS

KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target American.

Volume 75, Issue 5, Pages (March 2009)

Long-term Outcomes of Acute Kidney Injury: The Power and Pitfalls of Observational/Population-Based Studies Charuhas V. Thakar, MD American Journal.

Trial Quality in Nephrology: How Are We Measuring Up?

Volume 80, Issue 12, Pages (December 2011)

Multidrug-Resistant Organisms Within the Dialysis Population: A Potentially Preventable Perfect Storm David P. Calfee, MD, MS American Journal of Kidney.

American Journal of Kidney Diseases

Achieving Fairness in Access to Kidney Transplant: A Work in Progress

Quiz Page June 2009 American Journal of Kidney Diseases

James F. Winchester, MD, Thomas H. Hostetter, MD, Timothy W. Meyer, MD

This Month in AJKD American Journal of Kidney Diseases

How to Manage Functional Vitamin K Deficiency in CKD

Dialysis Research and N-of-1 Trials: Made for Each Other?

Quiz Page January 2010 American Journal of Kidney Diseases

Clinical Practice Recommendations For Peritoneal Dialysis Adequacy

A Decade After the KDOQI CKD Guidelines: Impact on the National Kidney Foundation's Kidney Early Evaluation Program (KEEP) Adam Whaley-Connell, DO, MSPH

Clinical Practice Guidelines for Peritoneal Dialysis Adequacy

Quiz page December 2003 American Journal of Kidney Diseases

Presentation transcript:

Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Patients With CKD: A Subgroup Analysis of the Randomized Controlled RxEACH Trial Yazid N. Al Hamarneh, Ross T. Tsuyuki, Charlotte A. Jones, Braden Manns, Marcello Tonelli, Nairne Scott-Douglass, Kailash Jindal, Wendy Tink, Brenda R. Hemmelgarn American Journal of Kidney Diseases Volume 71, Issue 1, Pages 42-51 (January 2018) DOI: 10.1053/j.ajkd.2017.07.012 Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions

Figure 1 Study flow. Randomization refers to the original randomization in RxEACH (The Alberta Vascular Risk Reduction Community Pharmacy Project). More information about the number of the overall patients screened has been reported elsewhere.18 Abbreviation: CKD, chronic kidney disease. American Journal of Kidney Diseases 2018 71, 42-51DOI: (10.1053/j.ajkd.2017.07.012) Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions

Figure 2 Primary outcome, the difference in change in estimated cardiovascular (CV) risk between the intervention and control groups at 3 months, found a relative risk reduction of 20% (absolute reduction, 5.03; 95% confidence interval, 3.4-6.65; P<0.001) in estimated CV risk over a 3-month period between the intervention and control groups, after adjusting for baseline values and the center effect. Vertical bars denote error bars. American Journal of Kidney Diseases 2018 71, 42-51DOI: (10.1053/j.ajkd.2017.07.012) Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions